Ragozzino M W, Melton L J, Kurland L T, Chu C P, Perry H O
N Engl J Med. 1982 Aug 12;307(7):393-7. doi: 10.1056/NEJM198208123070701.
Herpes zoster has been associated with immune suppression, as has an increased risk of cancer. To determine whether patients with herpes zoster are at increased risk for subsequent cancer, we followed 590 residents of Rochester, Minnesota, for 9389 person-years after the diagnosis of herpes zoster. Subsequent relative cancer risks, overall and by specific site, were determined for the entire cohort and selected subgroups. In addition, relative risks of cancer during various intervals after the diagnosis of herpes zoster were determined. The overall relative risk was 1.1 (95 per cent confidence interval, 0.9 to 1.3). Relative risks of specific cancer sites were not different from unity except for those for colon and bladder tumors in women, both of which were slightly elevated. Patients with disseminated, recurrent, or gangrenous zoster, with postherpetic neuralgia, and with ophthalmic zoster wee not at elevated risk for subsequent cancer. These findings do not support the investigation of patients for occult cancer at the time of diagnosis of herpes zoster or enhanced surveillance for cancer after such a diagnosis.
带状疱疹与免疫抑制有关，患癌风险也会增加。为了确定带状疱疹患者后续患癌风险是否增加，我们对明尼苏达州罗切斯特市的590名居民进行了跟踪，在其被诊断为带状疱疹后随访了9389人年。确定了整个队列以及选定亚组的后续相对癌症风险，包括总体风险和特定部位的风险。此外，还确定了带状疱疹诊断后不同时间段内的癌症相对风险。总体相对风险为1.1（95%置信区间为0.9至1.3）。除女性结肠癌和膀胱癌的相对风险略有升高外，特定癌症部位的相对风险与1无差异。患有播散性、复发性或坏疽性带状疱疹、带状疱疹后神经痛以及眼部带状疱疹的患者后续患癌风险并未升高。这些发现不支持在诊断带状疱疹时对患者进行隐匿性癌症检查，或在诊断后加强癌症监测。
